Search results | antibody drug conjugate


Cancer Monoclonal Antibody Partnering Terms and Agreements

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Antibody Partnering Terms & Agreements

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies


Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer

Seattle and Genentech expand antibody-drug conjugate collaboration

Seattle Genetics and Genentech have expanded their existing antibody-drug conjugate collaboration, in order to deliver additional preclinical ADC compounds.

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.


An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by …..

Current Agreements Deal Analysis Update : November 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

Q2 Partnering and Licensing Pharma trends of 2014

July 2014 By Raveena Bhambra Q2 was full of deals, coupled with the talk of potential deals, and overall it finished on a high with a large volume of agreements coming together in June.

Seattle Genetics : Biotech industry partnering activity 2009-2014

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment.

Current Agreements Deal analysis Update : July 2013

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in June 2013

Current Agreements Deal analysis Update : June 2013

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in May 2013

Top twenty partnering/licensing deals in 2012 had a combined value of over $20 billion

Analysis of data from the leading life science deals and alliances intelligence database Current Agreements and recently published Partnering Yearbook 2013 report series, shows that the top twenty partnering deals in the life sciences have a combined value of $20.6 billion


Sorry, your search returned no results.


Mersana collaborates with Endo to develop next-generation antibody drug conjugates

Mersana Therapeutics announced that it has entered into a collaboration agreement with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates.

Mersana expands fleximer antibody-drug conjugates pact with Takeda

Mersana Therapeutics have expanded their ongoing collaboration with Takeda Pharmaceutical to create novel Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology-relevant targets

Bayer pharma partners Seattle Genetics for collaboration on antibody-drug conjugate

Seattle Genetics has entered into a new antibody-drug conjugate collaboration with Bayer HealthCare, new pharma partners.

ImmunoGen announces antibody-drug conjugate collaboration with Eli Lilly, worth up to $200 million

ImmunoGen enters collaboration agreement with Eli Lilly and Company. Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel antibody-drug conjugate (ADC) anticancer therapeutics.

Genmab and Seattle Genetics expand antibody-drug conjugate (ADC)

Genmab and Seattle Genetics have announced they have entered into a second antibody-drug conjugate (ADC) research collaboration agreement.

Seattle Genetics and Genentech extend antibody-drug conjugate collaboration

Roche will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties’ existing antibody-drug conjugate (ADC) collaboration agreement.

Seattle Genetics and Agensys expand antibody-drug conjugate collaboration

Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

Seattle Genetics in antibody-drug conjugate collaboration with Millennium

Millennium will pay a $4 million upfront fee for an exclusive ADC license to an initial antigen expressed on solid tumors. Millennium also can exercise options for exclusive licenses to two other antigens upon payment of additional fees to Seattle Genetics.

Pharma partners, Menarini and Oxford Biotherapeutics, invest $1.1 billion in AML drug candidate

In October 2012, Pharma partners, Menarini and Oxford BioTherapeutics announce a strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

Genmab big biotech deals with ADC Therapeutics for oncology drug development

Genmab, a big biotech company, and ADC Therapeutics have entered biotech deals for the co-development of a new antibody-drug conjugate product combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology.